Amgen’s Phase 2a Study: A Potential Game-Changer in Autoimmune Disease Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. is conducting a Phase 2a clinical study titled ‘A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases.’ The study aims to evaluate the safety and tolerability of inebilizumab and blinatumomab in adults with active and refractory systemic lupus erythematosus (SLE) with nephritis and rheumatoid arthritis (RA). This research is significant as it could lead to new treatment options for these challenging autoimmune conditions.

The interventions being tested are inebilizumab, administered via intravenous infusion, and blinatumomab, given through subcutaneous injection. These drugs are designed to target and manage symptoms in patients with SLE and RA.

The study follows a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to provide insights into the effectiveness of these drugs in managing autoimmune diseases.

The study began on July 31, 2025, with an estimated completion date yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

The outcome of this study could significantly impact Amgen’s stock performance and investor sentiment, especially if the results indicate a breakthrough in treating autoimmune diseases. Competitors in the autoimmune treatment market will be closely monitoring these developments.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.